Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events

• Published in: Journal of the American Academy of Dermatology Vol. 88; no. 6; pp. 1271 - 1281
• Main Authors: Singer, Sean, Tan, Sally Y., Dewan, Anna K., Davids, Matthew, LaCasce, Ann S., Treon, Steven P., LeBoeuf, Nicole R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2023
• Subjects: Bruton tyrosine kinase inhibitor; BTK; cutaneous oncology; cutaneous toxicities; EGFR; ibrutinib; oncodermatology; skin toxicities; ibrutinib; skin toxicities; Bruton tyrosine kinase inhibitor; oncodermatology; cutaneous oncology; BTK; cutaneous toxicities; dAE; EGFR
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/j.jaad.2019.12.031

Ibrutinib is an oral inhibitor of Bruton tyrosine kinase that is approved by the United States Food and Drug Administration for several lymphoproliferative disorders and chronic graft-versus-host disease. To characterize cutaneous eruptions arising from ibrutinib and highlight overlap with epidermal growth factor receptor (EGFR) inhibitor–induced dermatologic adverse events. Single-center retrospective cohort of patients referred to the Skin Toxicities Program for treatment of cutaneous eruptions while taking ibrutinib. Among 19 patients, cutaneous eruptions manifested as facial-predominant papulopustular eruptions, petechiae, or ecchymoses, photosensitivity, panniculitis, xerosis, and clinical staphylococcal overgrowth. Most patients were able to continue ibrutinib therapy with focused treatment of their cutaneous toxicities. This study represents cases at a single tertiary care center and is limited to patients referred for toxicity. With the exception of petechiae, the cutaneous toxicities of ibrutinib overlap with those associated with selective EGFR inhibitors. We observed that these reactions can be successfully managed using approaches for EGFR inhibitor–induced cutaneous adverse events.